The MSD Animal Health Research Bursary for Veterinary Surgeons offers three awards, consisting of two ruminant bursaries and one companion animal bursary, of up to £4,000 each.
Each project should be completed within one to two years and the vet practitioner proposals will be judged by university academics to ensure independent assessment.
The companion animal research bursary will be assessed by the University of Nottingham Centre for Evidence-based Veterinary Medicine and the ruminant research bursary applications will be assessed by academic staff from the University of Bristol School of Veterinary Science.
Michelle Townley, veterinary advisor at MSD Animal Health (pictured right) said: "Our Vet Surgeon Research Bursaries have an important role to play in encouraging vet surgeons to continue to develop their research skills. New knowledge and good research skills form the life-blood of the industry so we’re keen to see proposals from both ruminant and companion animal practitioners. Being awarded a bursary has proved to be a career-changing experience for some participants so we’re keen to get as many applications as possible as part of our investment in the veterinary industry."
The deadline for entries is 30th November 2018. For more information, visit www.msdahresearchbursary.co.uk.
Eurovet Animal Health has launched Marbiflox 10%, a new marbofloxacin preparation for the treatment of respiratory infections in cattle and pigs.
Eurovet says the product can be used flexibly to provide a single dose treatment, with a concentration-dependent effect and a relatively short withdrawal period. Marbiflox can be administered intravenously, subcutaneously or intramuscularly in cattle or intramuscularly in pigs.
The main indications, with reference to good prescribing practice, are for the treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica, and Histophilus somni and acute forms of mastitis induced by marbofloxacin-sensitive Escherichia coli strains, during lactation. In pigs the main indication is in the treatment of MMA (metritis mastitis agalactia syndrome).
Further information about Marbiflox and the complete Eurovet range of products is available from Eurovet Animal Health. www.eurovet-ah.co.uk/.
Zoetis has relaunched a broad spectrum intramammary treatment for clinical mastitis, as Lincocin Forte S.
For vets seeking to prescribe an alternative first-choice tube, independent mastitis authority Dr Andrew Bradley suggests it could be a logical, efficacious option, offering the combination of two active ingredients (lincomycin and neomycin) not available in other intramammary tubes.1
Zoetis points to studies which show that In combination, these have been found to have much higher efficacy than the sum of the two parts against Staphylococci aureus.2&3
The company says Lincocin Forte is effective against Gram positive and Gram negative pathogens, in particular staphylococcus, streptococcus and coliform bacteria.
In trials, the treatment produced clinical cure rates 21% higher than an ampicillin-cloxacillin comparison in undifferentiated mastitis cases. As first choice treatment for S uberis clinical mastitis, bacteriological cure rates were similar to a penicillin-streptomycin comparison.4 Against S aureus, aesculin-positive streptococci, and E coli, combined clinical-bacteriological cure rates were 175%, 32% and 21% higher respectively with Lincocin Forte S than ampicillin-cloxacillin treatment.
Zoetis vet Jude Roberts said these findings underpin the treatment's relaunch and its suitability as a first choice therapy for new clinical mastitis cases.
Lincocin Forte S is a water-based formulation, which Jude says helps achieve good distribution in the udder and can be easier to infuse that oil-based tubes, particularly into hardened quarters associated with E coli infections.
Dr Bradley adds that water-based formulation is likely to be less irritant to udder tissues than oil-based tubes, and may improve distribution. He also suggests that "not being a fluoroquinolone or 3rd/4th generation cephalosporin may also help vets fulfil their 'appropriate and justified' prescribing responsibilities."
The recommended treatment is one 10ml syringe per infected quarter at each of three consecutive milkings. Milk from treated cows can be sold for human consumption 84-hours after the last treatment.References:
According to the NFU, last year farm animals worth an estimated £2.4 million pounds were severely injured or killed by dog attacks last year.
Obtaining forensic samples after an attack can be difficult because so often they happen in remote places and rural police can't always attend quickly enough to get a sample.
Dr. Nick Dawnay from Liverpool John Moores University therefore developed Early Evidence Kits to enable samples to be collected by vets, famers and police from the crime scene immediately.
Following a successful proof of concept in Wales, the research team is now trialling the kits in ten regions of England and Wales, with support from IVC Evidensia farm practices.
Over the next twelve months the trial will refine best practices for collecting forensic samples from livestock attack scenes.
David Martin, Group Head of Animal Welfare at IVC Evidensia said: “This project marks an exciting step forward in collecting and analysing canine DNA from livestock.
"It offers police and farmers a means to hold irresponsible dog owners culpable for the damage and losses caused by their pets.”
“As a profession we can support this research by ensuring samples are taken from as many cases within the relevant force areas as possible so that the team at John Moores gets sufficient material to be able to complete this project as soon as possible.
"All IVC Evidensia farm practices in the participating regions are being encouraged to use the kits and we want to ensure all farm practices in those regions know about this important project.”
It is hoped new legislation for England and Wales will be brought in to give police officers the power to take a DNA sample from a suspected dog to compare to canine DNA left at an attack scene.
Dave Allen, North Wales Police and NPCC Livestock Offence Working Group Secretary said: “These kits are an exciting development and can be utilised for an issue that causes major concern to our UK rural communities”.
Veterinary practices are now being encouraged help raise awareness of the project, particularly to encourage farmers to take part and use the kits to collect evidence in the following regions:
https://www.ljmu.ac.uk/about-us/news/articles/2024/5/17/forensic-science-to-help-farmers-foil-sheep-attacks
The company says it has redesigned the packaging to make it more distinctive, the idea being that it makes stock control in the practice and vaccine management on the farm easier and it also makes it easier for veterinary surgeons to identify and grab the right product off the shelf.
The new, bright red packaging for Bovilis IBR Marker Live is shown right. What do you think? Comment below.
According to Intervet, a study undertaken in Germany last summer has proven the efficacy of Butox SWISH at killing the midges responsible for carrying the bluetongue virus, when applied monthly to cattle. The study showed that even brief contact between a midge and hair from a treated animal killed midges rapidly for up to four weeks post-treatment.
The standard dose, applied in the usual way (on the neck and topline of the animal) delivers full-body coverage of Butox SWISH’s deltamethrin, helped partly by its unique micronised formulation. The product is also highly lipophilic which means it binds onto the natural oil secretions of the coat helping to improve coverage.
The trial used six heifers (each weighing around 400kg) treated with 30ml Butox SWISH (the standard fly dose and method of application). Two un-treated heifers were also studied for comparison.
During the five week period, contact between midges and treated hair caused immediate paralysis, and the midges then died at varying intervals depending on contact time and the number of days post-treatment with Butox SWISH. The trial verified the application of Butox SWISH monthly at the standard dose for cattle.
Trial director, Professor Mehlhorn suggested that producers should be prepared to reduce vector contact by removing their breeding habitats and combining this with the use of a knock-down treatment like Butox SWISH, which is the only product of its type which has proven efficacy against midges. Used in conjunction with vaccination, these measures may not stop the disease entering the herd, but will help reduce the spread of disease.
BCF has launched the Easi-Scan remote display, designed for on-farm use.
The company says the Easi-Scan offers unprecedented display performance, is very portable (weighing less than 2Kg) and very rugged. According to the company, Its 8.4" transflective LCD screen provides excellent quality images for fertility and pregnancy scanning meaning it can be used as the sole display for BCF's Easi-Scan and Duo-Scan ultrasound scanners. And with a dedicated channel button, you can switch between all available ultrasound channels, allowing you to view a number of examinations at once.
The Easi-Scan is also available with a Gorilla pod allowing it to be attached to railings and a carry strap.
Gavin Mitchell from BCF said: "At BCF innovation is key; we have invested a lot of time developing a remote display monitor that is well suited to the needs of the market. Through listening to our customers, we feel we have successfully achieved this. It is ideal for training purposes and viewing multiple exams. It is also the only wireless and splashproof remote ultrasound display on the market."
For more information call 01506 460023 or visit http://www.bcftechnology.com/.
Norbrook is expanding its NSAID range with the launch of Loxicom Injection for cattle, pigs and horses.
Norbrook says the new product, which will be available to veterinary surgeons from mid-October, offers treatment for a range of symptoms including pneumonia, acute mastitis and calf scour in cattle, swine locomotor diseases such as lameness and MMA syndrome, acute and chronic musculo-skeletal disorders and equine colic.
Rebecca Pullon, Norbrook Product Manager said: "Loxicom is our tried and trusted NSAID range which has been available in suspension or injection for cats and dogs and which has proven exceptionally popular with veterinary practices. According to the GFK data, Norbrook is the most successful generic manufacturer of Meloxicam, by some distance.
"I am delighted that we can now extend this range to include a Loxicom Injection for Cattle, Pigs and Horses, which I am confident will prove equally as popular."
"As a bio-equivalent product, Loxicom Injection for cattle, pigs and horses is as effective as the pioneer product. There is a misperception that a bioequivalent product is somehow inferior to the pioneer product, which is untrue. In order to attain a license, a company must prove that a bio-equivalent product is at least as effective as the pioneer. With Loxicom Injection for cattle, pigs and horses, it comes with the added reassurance that it has been produced by Norbrook, a world leader in animal health and veterinary pharmaceuticals manufacture."
Tri-Solfen contains lidocaine and bupivacaine to deliver rapid onset and prolonged local anaesthesia, adrenalin to reduce blood loss and cetrimide to lower the risk of infection.
Dechra says the gel is effective in 30 seconds, making it a practical tool to improve animal welfare via cutaneous and epilesional use.
Tri-Solfen was originally developed and launched in Australia by Medical Ethics, a company that specialises in pain management treatments for humans and animals.
According to the company, more than 100 million animals have been treated with Tri-Solfen in Australia, New Zealand and Portugal, where it is licensed for disbudding, dehorning, castration and general wound treatments in cattle, sheep, pigs and horses.
www.dechra.co.uk
There are three awards, two ruminant and one companion animal, of up to £4,000 each. Each project needs to be completed within 1-2 years and the veterinary practitioner proposals will be judged by university academics to ensure independent assessment.
Michelle Townley, Veterinary Advisor at MSD Animal Health (pictured right), herself a winner of an MSD bursary in 2001, said: "Our existing Research Bursaries are well-known amongst practitioners focusing on ruminants, having run for 6 years. For the first time, however, we are offering a broader level of support which includes both ruminant and companion animal practitioners. Our aim is to engage as many people as possible as we view our investment in research, and the pursuit of new knowledge, as the lifeblood of the veterinary industry."
The deadline for entries is 30th November 2017.
For further information, visit: www.msd-animal-health.co.uk/researchbursary.aspx.
The British Veterinary Association has reiterated its call for heightened vigilance following confirmation by AHVLA that Schmallenberg virus (SBV) has been detected on four sheep farms in Norfolk, Suffolk and East Sussex.
At this early stage the virus is understood to be vector-borne (although other routes of transmission have not been ruled out) and the clinical signs seen along with meteorological modelling of risk suggests that the four farms were affected during summer/autumn 2011, with congenital defects now becoming visible at lambing time.
Animals imported from the affected areas in northern Europe are also considered to be potentially at risk and their destination in the UK has been identified.
Congenital deformities and nervous defects are seen in newborn lambs, goat kids and calves. Clinical signs in affected cattle include pyrexia (fever), milk drop, and diarrhoea similar to what is often termed 'winter dysentery'. Farmers should be looking out for clusters of these signs within herds and flocks and reporting them to their veterinary surgeon.
Vets who are aware of suspicious clinical signs on their client's farms should report them to AHVLA, SAC or the local DARD divisional veterinary office for further investigation.
AHVLA, SAC and DARD have stated that they are keen to investigate potential cases and there will be no extra charge for the SBV tests that are undertaken, but their approaches are slightly different.
In England, Wales and Northern Ireland AHVLA and AFBI are carrying out SBV-only testing (ie to rule the disease in or out) free of charge but are charging the standard subsidised investigation charge for any additional diagnostic work.
In Scotland any carcases submitted for post mortem examinations are examined at the standard fee and all necessary examinations required by the VIO to investigate the case are included in the fee. SAC is not charging an additional fee for SBV testing.
Carl Padgett, President of the BVA, said: "The confirmation of Schmallenberg virus in sheep flocks in England is a reminder to vets and farmers across the UK to step up vigilance amongst ruminants.
"The BVA would encourage vets to speak to their local AHVLA, SAC or DARD team to discuss any suspect cases and consider submitting specimens for further investigation. We understand that in confirmed cases clinical signs occur in clusters and vets should ensure they know what to look for in both adult and perinatal ruminants.
"While the cases in the south east of England suggest the virus is vector-borne other potential routes of transmission are still being considered. Although the risk of zoonosis is believed to be very low it has not been ruled out and a sensible precautionary approach should be taken by those handling infected animals and specimens."
THE Society of Practising Veterinary Surgeons (SPVS) has published its annual Salary Survey, which provides a guide to what full time assistants are now earning.
The survey, which asked the society's members and anyone on the RCVS Register qualified for under three years to provide details about employees' salary levels, uniquely provides a breakdown of what full-time assistants are earning.
Respondents were asked to provide details of their basic salaries together with any benefits in kind such as rental accommodation, access to a car and CPD allowances, and total remuneration packages were calculated.
The survey, which is distributed along with the annual Fees Survey to SPVS members as a key benefit of membership, provides a breakdown of minimum, average and maximum salaries over categories ranging from location to the number of years qualified.
For the second year, student loan levels are featured, which, worryingly, highlights the increasing number of students graduating with large value loans.
Richard Hillman, SPVS President, said: "I very much welcome the publication of this important annual survey, which comes at a time when vet salaries and the fees we charge are under fire. It is interesting to note that the recent ‘league table' which effectively labeled us the ‘fat cats' among small businesses was based on the minority of corporate practices."
He added: "Our survey provides a very valuable base for employers to develop a transparent pay scheme and for employees to negotiate. It is particularly useful with new legislation on greater transparency of pay scales in businesses and the outlawing of salary ‘secrecy clauses' together with the Government's push for equality in male/female pay awards."
The SPVS annual Fees Survey, which provides a breakdown of fees charged across the small animal, cattle and equine sectors, will be published in September.
SPVS is run by practitioners for practitioners and if you'd like further information on the courses and membership benefits that SPVS offers, please contact the secretariat on 01926 410454 or visit the web site at www.spvs.org.uk
Vetoquinol is offering vets the opportunity to win one of five Selekt Cattle Pumps worth £240. In order to take part, you'll need to tell Vetoquinol about your experiences with Marbocyl 10% when treating acute mastitis.
Susan Mitchell, Vetoquinol's Large Animal Product Manager said: "This case study competition aims to gather information on the incidence and treatment of acute mastitis. Acute mastitis is a genuine veterinary emergency and rapid treatment is vitally important."
Vetoquinol says Marbocyl 10% has proven to be an effective treatment for acute E.coli mastitis, with a bactericidal action which does not liberate endotoxins. Administered intravenously, Marboyl 10% provides rapid improvement and an early return to milk production.
The company also says farmers have found toxaemic mastitis cases have benefited from the use of fluid therapy, using the Selekt Cattle Pump. Oral fluid therapy is a quick, easy and inexpensive option to intravenous treatment and improves the efficacy of hypertonic saline.
To enter the competition, visit http://www.vetoquinol.co.uk/, click the Marbocyl link on the right, and download and complete a brief case history.
Five winners will be chosen at random on 30th June 2010.
The new indication adds to the product’s existing claims for the treatment of respiratory disease in both cattle and swine.
The approval was based on data from a multi-centric field trial which enrolled more than 360 sheep on farms in the EU to evaluate the efficacy and safety of a single subcutaneous dose of gamithromycin to treat footrot. Study sites in the UK were included. Merial says the study demonstrated a statistically superior reduction in lameness and a numerically higher reduction in foot lesions versus tilmicosin. On day 21, 97.8% of Zactran treated sheep were no longer lame, compared to 93.3% of the tilmicosin group.
Sioned Timothy, Technical Manager UK and Ireland said: "This is an exciting development in the treatment of footrot throughout the UK and Europe.
"Footrot is an extremely painful disease and is recognised to have a significant impact on welfare and productivity. It can cause rapid weight loss and reduce reproduction rates, significantly impacting sheep farm profitability. Zactran is a highly effective, fast-acting, single shot injectable treatment, and provides a valuable tool for vets and farmers to use when implementing footrot control strategies.
Findlay MacBean, Head of Large Animal Business UK & Ireland, said: "Our goal at Merial is to improve the health and productivity of production animals through innovative solutions. We hope that the addition of this new indication for Zactran does just that, and gives us the opportunity to bring a cost-effective and practical solution for footrot in sheep to the marketplace.
"It also demonstrates our continued commitment to the sheep market and our ongoing investment in this sector. At Merial we always promote best practice, and believe that the addition of this product extension to our portfolio will help farmers achieve better health status in their flocks and ultimately improve farm profitability."
Zactran is available in the EU as a 150 mg/ml solution presented in 50ml, 150ml and 250ml bottles.
For further product information, see the SPC here.
The collaborative study, which was sponsored by Norbrook, involved each practice blood testing a cohort of six lambs on 25 individual farms from 16 weeks of age, to look for evidence of antibodies to liver fluke.
Only 11 farms had positive results in the period from June, up to December, with most only showing one or two lambs out of the six sero-converting later in the year. Even farms located reasonably close by showed positive cases months apart.
Mark Thompson of Craven Farm Vets in Yorkshire said, “I did not expect to see positive results as late in the year. I expected a positive result earlier (September/October) as the farm is a very wet farm with a long-standing issue with fluke. Also, the weather in the area has been ideal for the intermediate host and fluke development on the pasture.”
Emily Baxter of Drove Farm Vets in Wiltshire said she thinks there is scope to use the results to improve the timing of dosing with flukicides and more responsible use: “We will use the results from this year’s testing to re-evaluate the farm’s fluke control protocol which will help reduce the level of use of flukicides earlier in the season for years with similar weather patterns and assist in planning of strategic grazing.
"We’re looking forward to continuing our work this year, no two years are ever the same, that’s why monitoring is so important. It will allow both ourselves and our clients to build up a picture over time of what’s happening not only on their individual farms, but potentially down to field level! This will allow us to provide more conclusive recommendations. For now, it’s clear that testing has great promise as a means to provide tailored advice to farms on how to control fluke and use the flukicides available to us responsibly.”
Emily says it’s important that farmers do not stop using flukicides based on the results of this study nor assume that there is less risk: “We all know how significant the losses from acute and chronic fascioliasis can be. We therefore encourage farmers to talk to their vet before they change their flukicide treatment protocols and discuss the possibility of using serology as an adjunct to determine how and when they treat.”
Veterinary professionals can find out more about the fluke sentinel project at https://xlvets-farm.co.uk/fluke-sentinel or the XLVets community at https://www.xlvets.co.uk/the-boss/.
The University of Nottingham, with funding worth £2.2m, is to carry out a study of the most common cause of Bovine Mastitis in the UK - Streptococcus uberis (S. uberis). If researchers can identify which parts of the bacteria enable the infection their results could lead to the production of an effective vaccine.
James Leigh, Professor of Molecular Bacteriology, who has recently joined the School of Veterinary Medicine and Science, said: "We hope to uncover bacterial antigens of potential use in vaccines aimed at preventing bovine mastitis and provide a detailed understanding of how animals can fight off the disease."
S. uberis is responsible for a significant proportion of clinical mastitis worldwide - but unlike many other bacteria that cause the disease, S. uberis is also in the environment - it is found in pasture and bedding and can even colonise the cow at other body sites with no ill effect - so it is difficult to see how it can be controlled by changes to animal husbandry and milking-time hygiene.
With funding from the Biotechnology and Biological Sciences Research Council (BBSRC) the School of Veterinary Medicine and Science has established research laboratories at the Institute for Animal Health (IAH). The project is being conducted in collaboration with Dr Tracey Coffey's Bovine Genomics group based at IAH and other groups at the Royal Veterinary College, the US Department of Agriculture in the UK and the University of Oxford.
Professor Leigh said: "We will use state-of-the-art molecular technology to determine the differences between strains of S. uberis that can and cannot cause disease. Proteins that are only present in the disease causing strains hold the key to determining which components are essential for infection. We will show which of these proteins are most likely to make an effective vaccine by producing strains of S. uberis which lack the ability to produce each of these proteins; if a strain lacking a particular protein is less able to cause disease then this protein is important for the disease process and becomes a candidate for vaccine development."
The team also want to identify any parts of the immune response in the dairy cow which can be altered to prevent the disease - this information could subsequently be used to develop drugs that interfere with the chemical messages that lead to inflammation and therefore reduce the level of disease.
Used to treat calf diarrhoea, Locatim is an orally administered product, indicated for the reduction of mortality caused by enterotoxicosis associated with E. coli F5 (K99).
The product is made from the colostrum of high health status cows hyperimmunised against Rotavirus, Coronavirus and E.coli.
Locatim is designed to work alongside the dam’s colostrum, enhancing protection against gastro-intestinal infection and helping to sustain calf health in the critical neo-natal period.
For optimal effect, Forte says Locatim should be given within 4 hours of birth, but can be used up to 12 hours post-natally.
Forte says Locatim is not designed to replace anti-scour vaccination programmes, rather to act as an extremely useful adjunct in cases where the response to vaccines has been less than ideal.
The company says Locatim is also extremely useful in managing outbreaks of scour in unvaccinated herds by protecting those calves born before a new vaccination programme can take effect.
Locatim is available from all UK veterinary wholesalers.
For more information, contact your Forte Territory Manager or enquiries@fortehealthcare.com.
Origin (previously known as Westpoint) has announced that FarmVets SouthWest has joined the group, giving further geographical coverage to its veterinary practice network.
FarmVets SouthWest has practices at Ilminster and North Petherton in Somerset and Honiton in Devon.
Eoghan McAlonan, a director of the practice, said: "We are delighted to be joining Origin. The Origin group delivers the highest standards in veterinary services to UK agriculture, and we will bring our farmer friendly services to further enhance the groups activities".
In turn Origin says it plans to bring the wide benefits of group membership, including lab services, dairy consultancy and paraprofessional services, to further enhance the high level of service the vet team at Farmvets SouthWest provide to producers in Somerset and Devon.
Jon Mouncey, Managing Director of Westpoint Farmvets, said: "Working alongside our other Origin practices in the South West region, we can now offer all livestock producers our advanced services, ensuring their stock receive the very best in veterinary care. Our group offers a unique approach to integrated veterinary services and by applying the latest technology and research we ensure that animal health and welfare is optimised, delivering real value for our clients in a challenging agricultural climate."
With the end of the vector-free period and the threat of more cases of bluetongue, organisations from across all elements of the livestock sector have come together to launch a Joint campaign Against Bluetongue (JAB), with the strapline ‘don’t hesitate, vaccinate’.
The organisations involved, which represent livestock farmers, livestock markets and meat and dairy processing as well as the veterinary profession, all fully support the joint industry/Defra vaccination plan for bluetongue and are committed to working together on the campaign to achieve the mass vaccination of bluetongue susceptible animals, including goats and camelids.
JAB is now embarking on a major campaign to urge all farmers with susceptible livestock to vaccinate their animals as soon as vaccine is available and the BVA, along with our relevant specialist divisions, is committed to ensuring that vets have all the information in advance so that they are in a position to deal with their clients’ questions.
According to BVA President Nick Blayney: "Colleagues should be aware and look out for meetings being organised around the country, courtesy of the VLA and others, and led by vets where they can learn the latest information. The BVA website also carries useful and up-to-date information and links (http://www.bva.co.uk/policy/bluetongue_jab.asp). Practices are seen as the cornerstone of vaccine delivery, proper usage and monitoring for efficacy and BVA would encourage them to offer their clients the ability to register an interest in vaccine supply in advance of its arrival. Such a forward order book will speed up the delivery of the vaccine once it is available."
Boehringer Ingelheim Vetmedica has announced that it will be launching Bovela, a new viral diarrhoea (BVD) vaccine, to farmers during April 2015.
Allan Henderson from Boehringer said: "BVD remains the most common viral disease affecting cattle throughout Europe, despite vaccines being available for over 15 years. We asked farmers why this was the case and, without exception, they remarked that current vaccine protocols are unwieldy, requiring precise timings making them hard to follow.
"Bovela is a unique one-shot vaccine that can be used in cattle from three months of age and also whether pregnant or not. Other, currently available vaccines require a two-dose primary course with boosters annually or even every six months thereafter."
BVD is spread within herds and to new herds through the presence of persistently infected (PI) animals. PIs can look relatively healthy and show no outward signs of infection but, as they were exposed to the virus as a foetus, have become virus carriers. If they are born alive, they will shed virus consistently throughout their lives so perpetuating the cycle of infection.
Alan said: "The foetal control delivered by Bovela gives absolute confidence that cows will not produce PIs. This, alongside the drastically improved convenience will undoubtedly make Bovela the natural choice for many farmers, both on beef and dairy farms."
According to Boehringer, around 60% of cattle in the EU test positive for exposure to the BVD virus and, although BVD type 1 is currently the most common form, outbreaks of BVD type 2, were confirmed in 2013 and 2014 in Belgium, Germany and The Netherlands. BVD type 2 is generally a more serious disease, with high levels of mortality and while the virus has been identified in UK, it has not yet been identified as the cause of serious outbreaks of disease in cattle.
Alan said: "Bovela is the first and only vaccine in UK which has been proven to protect cattle from BVD type 1 and 2. It has been in development for 17 years and, gained a marketing authorisation following assessment of an unprecedented quantity of data generated in both beef and dairy herds.
"Work has looked at the efficacy of Bovela in preventing the production of PI calves and against type 1 and 2 BVD as well as confirming its efficacy in young calves as young as three months of age as their natural maternal protection wears off. Trials also confirmed vaccine safety generally and during various stages of pregnancy. We do not believe that any other BVD vaccine has been tested as rigorously."
The existing MSD Animal Health Connect Bursary and Ruminant Research Bursary have been combined into the new MSD Animal Health Research Bursary which is designed to support the future of the veterinary profession through research.
The student arm of the new Research Bursary will award £1,000 to the five best research project applications received from veterinary students across all UK veterinary schools, with an opportunity for an additional £1,000 top prize and £500 runner-up prize.
The veterinary surgeon arm of the Research Bursary will offer three awards, consisting of two ruminant awards and one companion animal award, of up to £4,000 each. The veterinary practitioner proposals will be judged by University academics to ensure independent assessment.
Michelle Townley, Veterinary Advisor at MSD Animal Health said: "Our existing Research Bursaries are well known amongst students and practitioners, having run for over 25 years for the student bursary and 6 years for the ruminant bursary. To increase our support for the veterinary profession through research we have decided to combine our Research Bursaries and add some new categories to help appeal to as wide an audience as possible. This way we can offer a broader level of support for both existing companion animal and ruminant practitioners and our veterinary surgeons of the future. We aim to engage as many people as possible so the MSD Animal Health Research Bursary will be supported by a new website page and social media package to encourage as much interest from students and practitioners as possible."
Student bursary applications are now invited, with a deadline for entries of Friday 26th May 2017. Veterinary practitioners will be invited to apply in September 2017.
For further details go to the MSD Animal Health Research Bursary website at www.msd-animal-health.co.uk/researchbursary.aspx.
Bayer Animal Health has announced the launch of Ceffect (cefquinome), for the treatment of bacterial infections in cattle and pigs caused by Gram-positive and Gram-negative micro-organisms sensitive to cefquinome.
Ceffect is available as a 25mg/ml suspension for injection of cattle and pigs, and as Ceffect LC, a 75mg intramammary ointment for lactating cows.
In cattle, Ceffect 25mg/ml suspension for injection is licensed for the treatment of respiratory disease caused by Pasteurella multocida and Mannheimia haemolytica, and also for the treatment of digital dermatitis, infectious bulbar necrosis, acute interdigital necrobacillosis, and acute E.coli mastitis with signs of systemic involvement.
In calves, Ceffect 25mg/ml suspension for injection is licensed for the treatment of E.coli septicaemia
In pigs, Ceffect 25mg/ml suspension for injection targets cefquinome-sensitive organisms including Pasteurella multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae and Streptococcus suis which can cause bacterial infections of the lungs and respiratory tract. It is also licensed for the treatment of Mastitis-Metritis-Agalactia syndrome (MMA) with involvement of E.coli, Staphylococcus spp., Streptococcus spp. and other cefquinome-sensitive organisms.
In piglets, Ceffect 25mg/ml suspension is licensed for the reduction of mortality in cases of meningitis caused by Streptococcus suis. For the treatment of arthritis caused by Streptococcus spp., E. coli and other cefquinome-sensitive organisms, and epidermitis (mild or moderate lesions) caused by Staphylococcus hyicus.
Ceffect LC, 75mg intramammary ointment for lactating cows also contains cefquinome and comes in individual 8g prefilled syringes for treatment of clinical mastitis caused by Streptococcus uberis, Streptococcus dysgalactiae, Staphylococcus aureus and E. coli, in lactating dairy cows.
For further product information, visit www.noahcompendium.co.uk or contact your local Bayer territory manager.
Esme grew up in Birmingham and spent much time in her teenage years working at the Domestic Fowl Trust caring for a range of rare breed poultry.
She said: "I didn’t grow up on a farm, but worked with chickens as a teenager and I love them to bits.
"They are amazing animals and I’ve wanted to work with them ever since.”
After graduating at the University of Liverpool, she spent two years with Howells Veterinary Services where she worked with clients to foster improved performance under an increasing drive for sustainability.
Now with St David’s Poultry Team in Yorkshire, she helps broiler clients in reducing viral challenge on farm to increase immunocompetence and so decrease susceptibility to other challenges.
She has also just become the youngest vet ever to achieve a Certificate in Advanced Veterinary Practice (Poultry), which she gained at the University of Liverpool.
The Young Farm Vet of the Year Awards is sponsored by Zoetis.
CEVA Animal Health is supplying a free, multi-dose injector gun with a self-sterilising needle system, with the purchase of bulk quantities of its luteolytic and uterotonic prostaglandin Enzaprost, while stocks last.
According to the company, the use of naturally occurring prostaglandins such as Enzaprost play an important role in any fertility management programme, working by causing lysis of the corpus luteum. Enzaprost can be used to control the timing of oestrus and synchronisation for AI; for the treatment of sub-oestrus or silent heat; for the induction of abortion up to day 120; for the induction of parturition and as an aid in the treatment of chronic metritis or pyometra where there is a functional or persistent corpus luteum. Natural prostaglandins also have a uterotonic effect which may be useful in the treatment of 'dirty' cows.
CEVA says any multi-cow injection programme has its risks, and that experience has shown that one in 250,000 injections can result in clostridial infection. Invariably this occurs in sequential animals, with the causal agent found in the bottle as a result of inadvertent needle contamination. Multi-dose syringes reduce the number of needle punctures into a bottle and the Sterimatic caps clean the needle before and after each injection helping to minimise the risk of infection. One Sterimatic cap can be used for 72 hours or up to 100 injections. The covered needle also provides increased safety for the operator, resulting in fewer needle stick and scratch injuries.
To find out how you can receive a free multi-dose injector with the Sterimatic needle protector system, which includes five caps and one needle protector, please contact your local CEVA territory manager
For copies of CEVA's fertility newsletters or for further product information please contact the large animal sales team or CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG.